

present disclosure is preferably any source material, particularly a vaccine, a source material comprising a vaccine and/or a component or source material for a vaccinating agent, preferably an antigen or a composition containing an antigen.

Moreover, the kit comprises a first container that is only partly filled with the first starting material and a second container holding the second starting material.

A container for the purposes of the present disclosure is preferably a structure enclosing a volume, preferably configured to receive a liquid, particularly a vessel, a bottle, a bag or the like.

The kit further comprises an adapter device for establishing a fluid connection, wherein the fluid connection can be established between the first and second containers. It is also preferable that the adapter device should be configured to establish a fluid connection between the interiors of the first container and the second container.

Moreover in the proposed kit at least one of the containers is closed off by a factory-provided closure device. Preferably, both containers are closed off by a factory-provided closure device. Preferably, an airtight and/or sterile closure is provided. In particular this may be a seal, a rubber stopper or the like, wherein the closure device can preferably be penetrated and/or pierced, particularly reversibly. In this way the containers, i.e. at least one of the containers, can be sealed in sterile manner.

It is envisaged that the second container can be connected to the first container by means of the adapter device, when the closure device is pierced for the first and/or only time, such that the second starting material enters the first container, particularly is transported therein, and there forms the vaccinating agent with the first starting material. The closure device or closure devices are thus preferably embodied to be penetrated or pierced by means of the adapter device. The adapter device is preferably configured to be able to penetrate and/or pierce the closure device or closure devices. In this way a fluid connection can be provided between the first and second containers.

In a first aspect, the present disclosure relates to a kit for preparing a vaccinating agent, particularly a kit for preparing a vaccinating agent for use in immunisation against the disease Porcine Circovirus Disease "PCVD" and/or Enzootic Pneumonia "EP", the kit comprising a first starting material, a second starting material different from the first, a first container only partly filled with the first starting material, and a second container comprising the second starting material and preferably an adapter device for providing a fluid connection between the first and second container, wherein at least one of the containers is closed off with a factory-provided closure device and the second container is connectable to the first container by means of the an adapter device for providing a fluid connection between the first and second container by piercing the closure device for the first and/or only time, such that the second starting material enters the first container and there forms the vaccinating agent with the first starting material, wherein the first starting material and the second starting material are liquid, the first starting material comprises only a first of the components Mycoplasma vaccine and Circovirus vaccine, the second starting material comprises only the other of the components Mycoplasma vaccine and Circovirus vaccine, and the total volume of the first container exceeds the volume of the first starting material at least by the volume of the second material.

With the kit according to the disclosure it is thus possible to prepare a vaccinating agent from two starting materials with only two containers and an adapter device, particularly for use in immunising against the diseases caused by infections with Porcine Circovirus and/or Mycoplasma hyopneumoniae, preferably for use in immunising against the diseases caused by infections with Porcine Circovirus and Mycoplasma hyopneumoniae. The kit also avoids the use of other incompatible starting materials, particularly by presenting the starting materials and containers in kit form.

It is also envisaged that a first starting material is used in a first container only partly filled with the first starting material and a second starting material that is different from the first is used in a second container holding the second starting material and an adapter device is used which is configured so as to establish a fluid connection between the first and second containers. At least one of the containers is closed off by a factory-provided closure device. A fluid connection between the first and second containers is produced by means of the adapter device when the closure device is penetrated for the first and/or only time, in order to transfer the second starting material through the adapter device and closure device into the first container and produce the vaccinating agent in the first container.

In a third aspect, the present disclosure relates to use of at least two starting materials for producing a vaccinating agent, preferably for, in particular, simultaneous, immunisation against the disease Porcine Circovirus Disease "PCVD" and/or Enzootic Pneumonia "EP" in pigs, in which, in order to produce the vaccinating agent, the starting materials are placed in containers and used with an adapter device, particularly using a kit as defined above, using a first starting material in a first container only partly filled with the first starting material and a second starting material different from the first in a second container comprising the second starting material, and an adapter device designed to provide a fluidic connection between the first and second container, at least one of the containers being closed off with a factory-provided closure device and forming with the adapter device, when the closure device is pierced for the first and/or only time, a fluid connection between the first and second container, in order to transfer the second starting material through the adapter device and the closure device into the first container and produce the vaccinating agent in the first container, wherein the first starting material and the second starting material are liquid, the first starting material comprises only a first of the components Mycoplasma vaccine and Circovirus vaccine, the second starting material comprises only the other of the components Mycoplasma vaccine and Circovirus vaccine, and the total volume of the first container exceeds the volume of the first starting material at least by the volume of the second material.

Another embodiment of the present disclosure that can also be implemented independently relates to a process for preparing a vaccinating agent from a first starting material and a second starting material different from the first, particularly for especially simultaneous immunisation against the disease Porcine Circovirus Disease "PCVD" and/or Enzootic Pneumonia "EP", preferably for particularly simultaneous immunisation against the diseases Porcine Circovirus Disease "PCVD" and Enzootic Pneumonia "EP". The vaccinating agent may be prepared using a kit as proposed.

Between a first container only partly filled with the first starting material and a second container holding the second starting material a fluid connection is established by an adapter device, such that the fluid connection between the first and second containers is established by means of the adapter device when at least one factory-provided closure device, which preferably closes off at least one of the containers, is penetrated or pierced for the first and/or only time by the adapter device. The second starting material is transferred or conveyed through the adapter device and the closure device into the first container. In the first container, the vaccinating agent is formed from the first starting material and the second starting material.

In a fourth aspect, the present disclosure relates to a process for preparing a vaccinating agent from a first starting material and with a second starting material different from the first, preferably for, in particular, simultaneous, immunisation against the disease Porcine Circovirus Disease "PCVD" and/or Enzootic Pneumonia "EP", particularly with a kit as defined above, wherein between a first container only partly filled with the first starting material and a second container comprising the second starting material a fluid connection is formed by an adapter device, such that, by means of the adapter device, when at least one factory-provided closure device of at least one of the containers is pierced for the first and/or only time a fluid connection is formed between the first and second container, and the second starting material is conveyed through the adapter device and the closure device into the first container, and in the first container the vaccinating agent is formed from the first and second starting material, wherein the first starting material and the second starting material are liquid, the first starting material comprises only a first of the components Mycoplasma vaccine and Circovirus vaccine, the second starting material comprises only the other of the components Mycoplasma vaccine and Circovirus vaccine, and the total volume of the first container exceeds the volume of the first starting material at least by the volume of the second material.

Preferably, the first and/or second starting material is or comprises a vaccine, an antigen and/or an antigen-containing composition. Moreover, the first starting material may differ from the second starting material. The first starting material may thus be or comprise a first vaccine, a first antigen and/or a composition containing a first antigen and the second starting material may be or comprise a second vaccine, different from the first, a second antigen different from the first and/or an antigen-containing composition, the antigen of which differs from that of the first antigen-containing composition. Preferably, the first vaccine and the second vaccine, or the first antigen and the second antigen, or the compositions containing the various antigens are for particularly simultaneous immunisation against various diseases or pathogens such as for example against the disease Porcine Circovirus Disease "PCVD" and Enzootic Pneumonia "EP", or for immunisation against Porcine Circovirus, preferably Porcine Circovirus type 2 and against Mycoplasmas, preferably against Mycoplasma hyopneumoniae. This makes it possible to produce a combination vaccine. The starting materials may contain other substances apart from vaccines, particularly water, adjuvants and/or excipients.

Patent Claims:

1. ~~Kit for preparing a vaccinating agent, particularly a kit for preparing a vaccinating agent~~
for use in immunisation against the disease Porcine Circovirus Disease "PCVD" and/or Enzootic
5 ~~Pneumonia "EP", the kit comprising a first starting material, a second starting material different~~
~~from the first, a first container only partly filled with the first starting material, and a second~~
~~container comprising the second starting material and preferably an adapter device for providing~~
~~a fluid connection between the first and second container,~~

10 wherein at least one of the containers is closed off with a factory provided closure device and
the second container is connectable to the first container by means of ~~the an~~ an adapter device for
providing a fluid connection between the first and second container by piercing the closure
device for the first and/or only time, such that the second starting material enters the first
15 container and there forms the vaccinating agent with the first starting material,
wherein the first starting material and the second starting material are liquid, the first starting
material comprises only a first of the components Mycoplasma vaccine and Circovirus vaccine,
the second starting material comprises only the other of the components Mycoplasma vaccine
and Circovirus vaccine, and the total volume of the first container exceeds the volume of the first
starting material at least by the volume of the second material.

20 ~~2. Kit according to claim 1, characterised in that the first and/or second starting material is~~
~~or comprises a vaccine.~~

25 ~~3. Kit according to claim 1 or 2, characterised in that the first starting material differs from~~
~~the second starting material.~~

30 ~~4. Kit according to one of the preceding claims, characterised in that the first starting~~
~~material comprises a first vaccine and the second starting material comprises a second vaccine~~
~~different from the first vaccine.~~

52. ~~Kit according to one of the preceding claims 1, characterised in that the first starting~~
material comprises the vaccine ~~only a first of the components Mycoplasma vaccine and~~
Circovirus vaccine, preferably in amounts of more than 30 % by weight, preferably more than 40
35 % by weight, particularly more than 50 % by weight; and/or less than 90 % by weight, preferably
less than 80 % by weight, particularly less than 70 % by weight.

6. ~~Kit according to claim 5, characterised in that the second starting material comprises~~
~~only the other of the components Mycoplasma vaccine and Circovirus vaccine.~~

40 ~~73. Kit according to one of the preceding claims 1 or 2, characterised in that the second~~
starting material comprises the vaccine ~~only one of the components Mycoplasma vaccine and~~
Circovirus vaccine, preferably in amounts of more than 30 % by weight, preferably more than 40
% by weight, particularly more than 50 % by weight; and/or less than 90 % by weight, preferably
45 less than 80 % by weight, particularly less than 70 % by weight.

84. ~~Kit according to one of the preceding claims, characterised in that the first starting~~
material, the second starting material and/or the vaccinating agent is a suspension, preferably
with vaccines and/or insoluble proteins, preferably in amounts of more than 30 % by weight,
preferably more than 40 % by weight, particularly more than 50 % by weight; and/or less than
50 90 % by weight, preferably less than 80 % by weight, particularly less than 70 % by weight.

95. Kit according to one of the preceding claims, characterised in that the ratio by volume of the first starting material to the second starting material is 3:1 to 1:3, preferably 2:1 to 1:2, particularly about 1:1.
- 5 | 406. Kit according to one of the preceding claims, characterised in that the first starting material and/or the second starting material and/or the vaccinating agent has a viscosity that is less than 10000 mPa·s, preferably less than 1000 mPa·s, particularly less than 500 mPa·s; and/or higher than 5 mPa·s, preferably higher than 10 mPa·s, particularly higher than 20 mPa·s, measured with a Brookfield viscometer according to EN ISO 2555 at 5°C.
- 10 | 417. Kit according to one of the preceding claims, characterised in that the first and/or second starting material is liquid at 2°C to 8°C; and/or has a melting point of less than 1°C, preferably less than 0°C, particularly less than -0.2°C; and/or higher than -1.5°C, preferably higher than -1.0°C, particularly higher than -0.8°C.
- 15 | 428. Kit according to one of the preceding claims, characterised in that the vaccinating agent has a characteristic colour different from the two starting materials; and/or in that the vaccinating agent has a colour or no colour, in contrast to at least one of the starting materials.
- 20 | 439. Kit according to one of the preceding claims, characterised in that mixing one of the starting materials with a third starting material that is different from the two starting materials produces no colour, or a colour that is different from the characteristic colour of the vaccinating agent.
- 25 | 4410. Kit according to one of the preceding claims, characterised in that the vaccinating agent is designed to prevent pigs from falling ill with *Mycoplasma hyopneumoniae* and/or Porcine Circovirus type 2.
- 30 | 4511. Kit according to one of the preceding claims, characterised in that the *Mycoplasma* vaccine contains one or more antigens of *Mycoplasma hyopneumoniae*, preferably in amounts of more than 30 % by weight, preferably more than 40 % by weight, particularly more than 50 % by weight; and/or less than 90 % by weight, preferably less than 80 % by weight, particularly less than 70 % by weight.
- 35 | 4612. Kit according to one of the preceding claims, characterised in that the Circovirus vaccine contains one or more antigens of Porcine Circovirus, preferably type 2, particularly Porcine Circovirus type 2 ORF2 protein, preferably in amounts of more than 30 % by weight, preferably more than 40 % by weight, particularly more than 50 % by weight; and/or less than 90 % by weight, preferably less than 80 % by weight, particularly less than 70 % by weight.
- 40 | 4713. Kit according to one of the preceding claims, characterised in that at least one of the starting materials and/or the vaccinating agent comprises a preferably polymeric adjuvant, particularly carbomer.

4814. Kit according to claim 4713, characterised in that at least one of the starting materials and/or the vaccinating agent comprises the adjuvant in amounts of more than 0.1 % by weight and/or less than 20 % by weight, preferably more than 1 % by weight and/or less than 10 % by weight, particularly more than 2 % by weight and/or less than 5 % by weight.
4915. Kit according to one of the preceding claims, characterised in that a preferably polymeric adjuvant, particularly carbomer, is formed in the vaccinating agent.
2016. Kit according to one of the preceding claims, characterised in that the Mycoplasma vaccine and/or the Circovirus vaccine contains formaldehyde in a concentration of less than 2.5 mg/m³, preferably less than 1.5 mg/m³, particularly 0.74 mg/m³ or less.
2417. Kit according to one of the preceding claims, characterised in that the first starting material contains water in a concentration of at least 20 % by weight, preferably at least 30 % by weight, particularly at least 40 % by weight; and/or at most 80 % by weight, preferably at most 70 % by weight, particularly at most 60 % by weight.
2218. Kit according to one of the preceding claims, characterised in that the first starting material contains one or more excipients, particularly preservatives, antioxidants and/or emulsifier, each preferably in a concentration of at least 0.1 % by weight, preferably at least 0.2 % by weight, particularly at least 0.3 % by weight; and/or at most 10 % by weight, preferably at most 5 % by weight, particularly at most 3 % by weight.
- ~~23. Kit according to one of the preceding claims, characterised in that the total volume of the first container exceeds the volume of the first starting material at least by the volume of the second starting material.~~
2419. Kit according to one of the preceding claims, characterised in that the first container is filled with the first starting material in an amount of less than 70 %, preferably less than 50 %, particularly less than 45 %.
2520. Kit according to one of the preceding claims, characterised in that the first container contains gas, preferably protective gas.
2621. Kit according to claim 2520, characterised in that the volume of the gas corresponds at least to the volume of the second starting material in the second container.
2722. Kit according to claim 25-20 or 2621, characterised in that the volume of the gas in the first container exceeds the volume of the second starting material by more than 2 %, preferably more than 5 %, particularly more than 8 % and/or less than 80 %, preferably less than 50 %, particularly less than 40 % or 30 %.
2823. Kit according to one of claims 25-20 to 2722, characterised in that the adapter device is configured so that during the transfer of the second starting material into the first container the gas or protective gas passes, particularly is transported, from the first container into the second container.

| ~~3024~~. Kit according to one of the preceding claims, characterised in that the adapter device is configured for preferably fluidically connecting the inner spaces formed by the containers.

5 | ~~3025~~. Kit according to one of the preceding claims, characterised in that the adapter device comprises a fluid channel for providing a fluidic connection between the inner spaces formed by the containers.

| ~~3126~~. Kit according to one of the preceding claims, characterised in that the adapter device comprises a venting or exhaust device.

10 | ~~3227~~. Kit according to claim ~~3126~~, characterised in that the adapter device comprises a channel for venting or exhaust.

15 | ~~3328~~. Kit according to claim ~~3025~~ and according to claim ~~3126~~ or ~~3227~~, characterised in that the venting or exhaust device, particularly the channel for venting or exhaust, is provided in addition to the fluid channel of the adapter device, particularly parallel thereto.

20 | ~~3429~~. Kit according to claim ~~3025~~ and one of claims ~~3126~~ to ~~3328~~, characterised in that one opening of the channel for venting or exhaust is set back, in respect of the outlet opening of the fluid channel on the side facing the first container, in the direction of the main extent of the adapter device,
and/or

25 | an opening of the channel for venting or exhaust facing the second container is arranged on the side of the outlet opening of the fluid channel facing the second container, which faces the second container, facing the open end of the adapter device.

30 | ~~3530~~. Kit according to one of claims ~~3126~~ to ~~3429~~, characterised in that the venting or exhaust device is configured for in particular fluidically connecting the inner spaces formed by the containers.

35 | ~~3631~~. Kit according to one of the preceding claims, characterised in that the adapter device comprises two adapter elements forming a fluid channel and/or venting or exhaust device, associated with the containers, preferably configured as a transfer needle, hollow needle and/or spike.

| ~~3732~~. Kit according to claim ~~3631~~, characterised in that between the adapter elements is provided a tube or pipe, particularly moulded thereon, preferably for extending the fluid channel.

40 | ~~3833~~. Kit according to one of the preceding claims, characterised in that the adapter device is configured to be specific to the first container and/or second container.

| ~~3934~~. Kit according to claim ~~3833~~, characterised in that at least one adapter element is configured mechanically to be specific to one of the containers.

4035. Kit according to claim ~~38-33~~ or ~~39~~34, characterised in that the introduction of substances other than the first and/or second starting material into the first and/or second container is prevented.
- 5 | 4136. Kit according to one of the preceding claims, characterised in that the adapter device is embodied to form a connection solely between the first and second container, particularly with exclusion of the surrounding atmosphere.
- 10 | 4237. Kit according to one of the preceding claims, characterised in that the second starting material enters the first container under the effect of gravity.
- | 4338. Kit according to one of the preceding claims, characterised in that at least one of the containers, particularly the second container, is flexibly deformable.
- 15 | 4439. Kit according to one of the preceding claims, characterised in that the first container, the second container, the closure device and/or the connecting device consists at least substantially of HDPE, EVA, halobutyl type 1 rubber and/or siliconised chlorobutyl.
- 20 | 4540. Kit according to one of the preceding claims, characterised in that the closure device comprises or consists of a rubber stopper.
- | 4641. Kit according to claim 4540, characterised in that the rubber stopper comprises or at least substantially consists of halobutyl type 1 rubber.
- 25 | 4742. Kit according to one of the preceding claims, characterised in that for the preparation the first container, the second container and the adapter device form a sealed assembly, preferably with a common packaging.
- 30 | 4843. Kit according to one of the preceding claims, characterised in that the vaccinating agent is intended for preventing disease in pigs caused by infection with porcine Circovirus type 2 and/or Mycoplasma hyopneumoniae.
- | 4944. Kit according to one of the preceding claims, characterised in that the first container can be used in or with a preferably multiple-use injection device, particularly an injection gun, pressure injector and/or self-filling syringe.
- 35 | 5045. Kit according to one of the preceding claims, characterised in that, for use in or with a particularly multiple-use injection device, particularly an injection gun, pressure injector and/or self-filling syringe, the first container can be connected in airtight manner to a receptacle of the injection device.
- 40 | 5146. Kit according to one of the preceding claims, characterised in that the first container is formed in a neck or mouth region, particularly by means of the closure device for connection to a particularly multiple-use injection device, particularly an injection gun, pressure injector and/or self-filling syringe.
- 45

5247. Kit according to one of the preceding claims, characterised in that the longitudinal extent and/or the diameter of the first container is designed for use in a particularly multiple-use injection device, particularly an injection gun, pressure injector and/or self-filling syringe.
- 5 5348. Kit according to one of the preceding claims, characterised in that the first container has a diameter of more than 1 cm, preferably more than 2 cm, particularly more than 3 cm; and/or less than 10 cm, preferably less than 8 cm, particularly less than 6 cm.
- 10 5449. Kit according to one of the preceding claims, characterised in that the first container has a longitudinal extent that is more than 3 cm, preferably more than 5 cm, particularly more than 6 cm and/or less than 30 cm, preferably less than 25 cm, particularly less than 20 cm.
- 15 5550. Use of a kit, particularly according to one of the preceding claims, for producing and/or preparing a vaccinating agent, preferably for, in particular, simultaneous immunisation against the disease Porcine Circovirus Disease "PCVD" and/or Enzootic Pneumonia "EP".
- 20 5651. Use of at least two starting materials for producing a vaccinating agent, preferably for, in particular, simultaneous, immunisation against the disease Porcine Circovirus Disease "PCVD" and/or Enzootic Pneumonia "EP" in pigs, in which, in order to produce the vaccinating agent, the starting materials are placed in containers and used with an adapter device, particularly using a kit according to one of claims 1 to 5449,
- 25 using a first starting material in a first container only partly filled with the first starting material and a second starting material different from the first in a second container comprising the second starting material, and an adapter device designed to provide a fluidic connection between the first and second container,
- 30 at least one of the containers being closed off with a factory provided closure device and forming with the adapter device, when the closure device is pierced for the first and/or only time, a fluid connection between the first and second container, in order to transfer the second starting material through the adapter device and the closure device into the first container and produce the vaccinating agent in the first container,
- 35 wherein the first starting material and the second starting material are liquid, the first starting material comprises only a first of the components Mycoplasma vaccine and Circovirus vaccine, the second starting material comprises only the other of the components Mycoplasma vaccine and Circovirus vaccine, and the total volume of the first container exceeds the volume of the first starting material at least by the volume of the second material.
- 40 5752. Use according to one of claim 5651, characterised in that the adapter device is used to penetrate the closure device.
5853. Use according to claim 56-51 or 5752, characterised in that the adapter device is used to penetrate the closure devices of both containers, preferably for the first and/or only time.
- 45 5954. Use according to one of claims 56-51 to 5853, characterised in that the adapter device is used first to penetrate the closure device of the second container and then the closure device of the first container, preferably for the first and/or only time.

6055. Use according to one of claims 56-51 to 5954, characterised in that the adapter device is used to produce a fluid connection between the containers such that the starting material passes from the second container into the first container under the effect of gravity.
- 5 | 6456. Use according to one of claims 56-51 to 6055, characterised in that the first container is moved during and/or after the transfer of the second starting material into the first container, in order to achieve and/or speed up homogeneous mixing.
- 10 | 6257. Use according to one of claims 56-51 to 6456, characterised in that the first container is used with an injection device, more particularly is connected thereto.
- 15 | 6358. Use according to one of claims 56-51 to 6257, characterised in that the first container is used in or with a preferably multiple-use injection device, particularly an injection gun, pressure injector and/or self-filling syringe.
- 20 | 6459. Use according to one of claims 56-51 to 6358, characterised in that the first container is configured for use in or with a preferably multiple-use injection device, particularly an injection gun, pressure injector and/or self-filling syringe.
- 25 | 6560. Use according to one of claims 56-51 to 6459, characterised in that the first container is configured in a neck or mouth region for connection to a particularly multiple-use injection device, particularly an injection gun, pressure injector and/or self-filling syringe.
- 30 | 6661. Use according to one of claims 56-51 to 6560, characterised in that the longitudinal extent and/or diameter of the first container is designed for use in a particularly multiple-use injection device, particularly an injection gun, pressure injector and/or self-filling syringe.
- 35 | 6762. Use according to one of claims 56-51 to 6661, characterised in that the first container has a diameter of more than 1 cm, preferably more than 2 cm, particularly more than 3 cm and/or less than 10 cm, preferably less than 8 cm, particularly less than 6 cm.
- 40 | 6863. Use according to one of claims 56-51 to 6762, characterised in that the first container has a longitudinal extent which is more than 3 cm, preferably more than 5 cm, particularly more than 6 cm and/or less than 30 cm, preferably less than 25 cm, particularly less than 20 cm.
- 45 | ~~69. Use according to one of claims 56 to 68, characterised in that the first and/or second starting material is or comprises a vaccine.~~
- ~~70. Use according to one of claims 56 to 69, characterised in that the first starting material differs from the second starting material.~~
- ~~71. Use according to one of claims 56 to 70, characterised in that the first starting material comprises a first vaccine and the second starting material comprises a second vaccine that is different from the first vaccine.~~

7264. Use according to one of claims ~~56-51~~ to 7463, characterised in that the first starting material the vaccine ~~comprises only a first of the components Mycoplasma vaccine and Circovirus vaccine, preferably in amounts of more than 30 % by weight, preferably more than 40 % by weight, particularly more than 50 % by weight; and/or less than 90 % by weight, preferably less than 80 % by weight, particularly less than 70 % by weight.~~

~~73. Use according to one of claims 56 to 72, characterised in that the second starting material comprises only the other of the components Mycoplasma vaccine and Circovirus vaccine.~~

7465. Use according to one of claims ~~56-51~~ to 7364, characterised in that the second starting material the vaccine ~~comprises only one of the components Mycoplasma vaccine and Circovirus vaccine, preferably in amounts of more than 30 % by weight, preferably more than 40 % by weight, particularly more than 50 % by weight; and/or less than 90 % by weight, preferably less than 80 % by weight, particularly less than 70 % by weight.~~

7566. Use according to one of claims ~~56-51~~ to 7465, characterised in that the first starting material, the second starting material and/or the vaccinating agent is a suspension, preferably with vaccines and/or insoluble proteins, preferably in amounts of more than 30 % by weight, preferably more than 40 % by weight, particularly more than 50 % by weight; and/or less than 90 % by weight, preferably less than 80 % by weight, particularly less than 70 % by weight.

7667. Use according to one of claims ~~56-51~~ to 7566, characterised in that the ratio by volume of the first starting material to the second starting material is 3:1 to 1:3, preferably 2:1 to 1:2, particularly about 1:1.

7768. Use according to one of claims ~~56-51~~ to 7667, characterised in that the first starting material and/or the second starting material and/or the vaccinating agent has a viscosity which is less than 10000 mPa·s, preferably less than 1000 mPa·s, particularly less than 500 mPa·s; and/or higher than 5 mPa·s, preferably higher than 10 mPa·s, particularly higher than 20 mPa·s, measured with a Brookfield viscometer according to EN ISO 2555 at 5°C.

7869. Use according to one of claims ~~56-51~~ to 7768, characterised in that the first and/or second starting material is liquid at 2°C to 8°C; and/or has a melting point of less than 1°C, preferably less than 0°C, particularly less than -0.2°C and/or higher than -1.5°C, preferably higher than -1.0°C, particularly higher than -0.8°C.

7970. Use according to one of claims ~~56-51~~ to 7869, characterised in that the vaccinating agent has a characteristic colour different from both starting materials; and/or in that the vaccinating agent has a colour or no colour, in contrast to at least one of the starting materials.

8071. Use according to one of claims ~~56-51~~ to 7970, characterised in that mixing one of the starting materials with a third starting material different from the two starting materials produces no colour or a different colour from the one that is characteristic of the vaccinating agent.

- | 8472. Use according to one of claims ~~56-51~~ to ~~8071~~, characterised in that the vaccinating agent is intended for preventing disease in pigs caused by infection with Mycoplasma hyopneumoniae and/or Porcine Circovirus type 2.
- 5 | 8273. Use according to one of claims ~~56-51~~ to 8472, characterised in that the Mycoplasma vaccine contains one or more antigens of Mycoplasma hyopneumoniae, preferably in amounts of more than 30 % by weight, preferably more than 40 % by weight, particularly more than 50 % by weight; and/or less than 90 % by weight, preferably less than 80 % by weight, particularly less than 70 % by weight.
- 10 | 8374. Use according to one of claims ~~56-51~~ to 8273, characterised in that the Circovirus vaccine contains one or more antigens of Porcine Circovirus, preferably type 2, particularly porcine Circovirus type 2 ORF2 protein, preferably in amounts of more than 30 % by weight, preferably more than 40 % by weight, particularly more than 50 % by weight; and/or less than 90 % by weight, preferably less than 80 % by weight, particularly less than 70 % by weight.
- 15 | 8475. Use according to one of claims ~~56-51~~ to 8374, characterised in that at least one of the starting materials and/or the vaccinating agent comprises a preferably polymeric adjuvant, particularly carbomer.
- 20 | 8576. Use according to claim 8475, characterised in that at least one of the starting materials and/or the vaccinating agent comprises the adjuvant in amounts of more than 0.1 % by weight and/or less than 20 % by weight, preferably more than 1 % by weight and/or less than 10 % by weight, particularly more than 2 % by weight and/or less than 5 % by weight.
- 25 | 8677. Use according to one of claims ~~56-51~~ to 8576, characterised in that a preferably polymeric adjuvant, particularly carbomer, is formed in the vaccinating agent.
- | 8778. Use according to one of claims ~~56-51~~ to 8677, characterised in that the Mycoplasma vaccine and/or the Circovirus vaccine contains formaldehyde in a concentration of less than 2.5 mg/m³, preferably less than 1.5 mg/m³, particularly 0.74 mg/m³ or less.
- 30 | 8879. Use according to one of claims ~~56-51~~ to 8778, characterised in that the first starting material contains water in a concentration of at least 20 % by weight, preferably at least 30 % by weight, particularly at least 40 % by weight; and/or at most 80 % by weight, preferably at most 70 % by weight, particularly at most 60 % by weight.
- 35 | 8980. Use according to one of claims ~~56-51~~ to 8879, characterised in that the first starting material contains one or more excipients, particularly preservatives, antioxidants and/or emulsifier, each preferably in a concentration of at least 0.1 % by weight, preferably at least 0.2 % by weight, particularly at least 0.3 % by weight; and/or at most 10 % by weight, preferably at most 5 % by weight, particularly at most 3 % by weight.
- 40

~~90. Use according to one of claims 56 to 89, characterised in that the total volume of the first container exceeds the volume of the first starting material at least by the volume of the second starting material.~~

5 | ~~9181.~~ Use according to one of claims ~~56-51~~ to ~~9080~~, characterised in that the first container is filled with the first starting material by an amount of less than 70 %, preferably less than 50%, particularly less than 45 %.

10 | ~~9282.~~ Use according to one of claims ~~56-51~~ to ~~9181~~, characterised in that the first container contains gas, preferably protective gas.

| ~~9383.~~ Use according to claim ~~9282~~, characterised in that the volume of the gas corresponds at least to the volume of the second starting material in the second container.

15 | ~~9484.~~ Use according to claim ~~92-82~~ or ~~9383~~, characterised in that the volume of the gas in the first container exceeds the volume of the second starting material by more than 2 %, preferably more than 5 %, particularly more than 8 % and/or less than 80 %, preferably less than 50 %, particularly less than 40 % or 30 %.

20 | ~~9585.~~ Use according to one of claims ~~92-82~~ to ~~9484~~, characterised in that the adapter device is configured so that during the transfer of the second starting material into the first container the gas or protective gas passes, particularly is transported, from the first container into the second container.

25 | ~~9686.~~ Use according to one of claims ~~56-51~~ to ~~9585~~, characterised in that the adapter device is configured for preferably fluidically connecting the inner spaces formed by the containers.

30 | ~~9787.~~ Use according to one of claims ~~56-51~~ to ~~9686~~, characterised in that the adapter device comprises a fluid channel for providing a fluidic connection between the inner spaces formed by the containers.

| ~~9888.~~ Use according to claim ~~9887~~, characterised in that the adapter device comprises a venting or exhaust device.

35 | ~~9989.~~ Use according to one of claims ~~56-51~~ to ~~9888~~, characterised in that the adapter device comprises a channel for venting or exhaust.

40 | ~~10090.~~ Use according to claim ~~97-87~~ and claim ~~98-88~~ or ~~9989~~, characterised in that the venting or exhaust device, particularly the channel for venting or exhaust, is provided in addition to the fluid channel of the adapter device, particularly parallel thereto.

45 | ~~10191.~~ Use according to claim ~~97-87~~ and one of claims ~~98-88~~ to ~~10090~~, characterised in that one opening of the channel for venting or exhaust is set back, in respect of the outlet opening of the fluid channel on the side facing the first container, in the direction of the main extent of the adapter device.

- | 40292. Use according to one of claims 97-87 to 40191, characterised in that the venting or exhaust device is configured for in particular fluidically connecting the inner spaces formed by the containers.
- 5 | 40393. Use according to one of claims 97-87 to 40292, characterised in that the adapter device comprises two adapter elements forming a fluid channel and/or venting or exhaust device, associated with the containers, preferably configured as a transfer needle, hollow needle and/or spike.
- 10 | 40494. Use according to claim 40393, characterised in that between the adapter elements is provided a tube or pipe, particularly moulded thereon, preferably for extending the fluid channel.
- | 40595. Use according to one of claims 56-51 to 40494, characterised in that the adapter device, particularly an adapter element, is configured to be specific to the first container and/or second container.
- 15 | 40696. Use according to claim 404-94 or 40595, characterised in that at least one adapter element is configured mechanically to be specific to one of the containers.
- 20 | 40797. Use according to one of claims 56-51 to 40696, characterised in that the introduction of substances other than the first and/or second starting material into the first and/or second container is prevented.
- | 40898. Use according to one of claims 56-51 to 40797, characterised in that the adapter device is embodied to form a connection solely between the containers, particularly with exclusion of the surrounding atmosphere.
- 25 | 40999. Use according to one of claims 56-51 to 40898, characterised in that the second starting material enters the first container under the effect of gravity.
- 30 | 410100. Use according to one of claims 56-51 to 40999, characterised in that at least one of the containers, particularly the second container, is flexibly deformable.
- | 411101. Use according to one of claims 56-51 to 410100, characterised in that the first container, the second container, the closure device and/or the connecting device consists at least substantially of HDPE, EVA, halobutyl type 1 rubber and/or siliconised chlorobutyl.
- 35 | 412102. Use according to one of claims 56-51 to 411101, characterised in that the closure device comprises or consists of a rubber stopper.
- 40 | 413103. Use according to claim 412102, characterised in that the rubber stopper comprises or at least substantially consists of halobutyl type 1 rubber.
- | 414104. Use according to one of claims 56-51 to 413103, characterised in that for the preparation the first container, the second container and the adapter device form a sealed assembly, preferably with a common packaging.
- 45

445105. Use according to one of claims ~~56-51~~ to 444104, characterised in that the vaccinating agent is intended for preventing disease in pigs caused by infection with porcine Circovirus type 2 and/or Mycoplasma hyopneumoniae.

5 446106. Process for preparing a vaccinating agent from a first starting material and with a second starting material different from the first, preferably for, in particular, simultaneous, immunisation against the disease Porcine Circovirus Disease "PCVD" and/or Enzootic Pneumonia "EP", particularly with a kit according to one of claims 1 to 54,

10 wherein between a first container only partly filled with the first starting material and a second container comprising the second starting material a fluid connection is formed by an adapter device, such that, by means of the adapter device, when at least one factory-provided closure device of at least one of the containers is pierced for the first and/or only time a fluid connection is formed between the first and second container, and

15 the second starting material is conveyed through the adapter device and the closure device into the first container, and

20 in the first container the vaccinating agent is formed from the first and second starting material,

25 wherein the first starting material and the second starting material are liquid, the first starting material comprises only a first of the components Mycoplasma vaccine and Circovirus vaccine, the second starting material comprises only the other of the components Mycoplasma vaccine and Circovirus vaccine, and the total volume of the first container exceeds the volume of the first starting material at least by the volume of the second material.

447107. Process according to claim 446106, characterised in that closure devices of both containers are penetrated with the adapter device, preferably for the first and/or only time.

30 448108. Process according to claim 446106 or 447107, characterised in that first the closure device of the second container and then the closure device of the first container is penetrated by the adapter device, preferably for the first and/or only time, or *vice versa*.

35 449109. Process according to one of claims 446106 to 448108, characterised in that a fluid connection is provided between the containers such that the second starting material passes from the second container into the first container under the effect of gravity.

40 420110. Process according to one of claims 446106 to 449109, characterised in that the first container is moved during and/or after the transfer of the second starting material into the first container, so as to achieve or speed up a homogeneous reaction, particularly dissolving or mixing.

45 424111. Process according to one of claims 446106 to 420110, characterised in that the first container is placed in or on an injection device.

422112. Process according to one of claims 446106 to 424111, characterised in that the first container is placed in or on a preferably multiple-use injection device, particularly an injection gun, pressure injector and/or self-filling syringe.